HopeStage
Back to all studies
CompletedEUCTR 2013-000212-22

A double-blind, randomised, placebo-controlled, parallel group study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder

This historical record does not confirm current site availability.

Historical research recordMultiple countries
The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Who was this study for?

This study was for people with schizophrenia. Other eligibility criteria applied.

Listed locations
Poland · Romania and 1 more location
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNot clearly listed
Recruitment status
Completed
Enrollment listed in the registry
78
Sponsor
GW Research Ltd
Sponsor type
Other organization
Study type
Biological
Intervention type
Biological
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United Kingdom, Poland, Romania
Age range
Not clearly listed
Official registry ID
EUCTR 2013-000212-22
Official title
Show the full official title

A double-blind, randomised, placebo-controlled, parallel group study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Poland · Romania · United Kingdom

Registry details
Historical country statuses

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is GW Research Ltd.

Who was this study for?

This study was for people with schizophrenia. Other eligibility criteria applied.

Want to explore more studies?

Explore studies